Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors

被引:40
|
作者
Teixeira, C. [1 ]
Serradji, N. [1 ]
Maurel, F. [1 ]
Barbault, F. [1 ]
机构
[1] Univ Paris Diderot, Lab ITODYS, F-75013 Paris, France
关键词
gp120; inhibitors; 3D-QSAR; CoMFA; CoMSIA; Docking; MOLECULAR SIMILARITY INDEXES; ENVELOPE GLYCOPROTEIN; VIRAL ENVELOPE; ARGININE CONJUGATE; ANALYSIS COMSIA; CD4; RECEPTOR; BINDING; BMS-378806; DYNAMICS; FUSION;
D O I
10.1016/j.ejmech.2009.03.028
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
BMS-378806 (BMS-806) is a small molecule that blocks the binding of host-cell CD4 with viral gp120 protein and therefore inhibits the first steps of HIV-1 infection. Recently, 36 analogs compounds of BMS-806 were synthesized and their biological activity evaluated. Based on these compounds, a molecular docking was firstly performed with BMS-806 to the gp120 cavity in order to get a representative ligand conformation for the 3D-QSAR process. Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) were then conducted for these 36 compounds. CoMFA and CoMSIA models give reliable correlative and predictive abilities but the CoMFA model performance was slightly better than CoMSIA. CoMFA contours were analysed and have been correlated to the gp120 viral protein. The discussion indicates several key fragment positions on the ligands and their implications on the gp120 protein binding. The computational approach used in this paper provides reliable clues for further design of small molecules gp120/CD4 inhibitors based on the BMS-806. (C) 2009 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:3524 / 3532
页数:9
相关论文
共 50 条
  • [1] Molecular docking and 3D-QSAR studies of HIV-1 protease inhibitors
    Vijay M. Khedkar
    Premlata K. Ambre
    Jitender Verma
    Mushtaque S. Shaikh
    Raghuvir R. S. Pissurlenkar
    Evans C. Coutinho
    Journal of Molecular Modeling, 2010, 16 : 1251 - 1268
  • [2] Molecular docking and 3D-QSAR studies of HIV-1 protease inhibitors
    Khedkar, Vijay M.
    Ambre, Premlata K.
    Verma, Jitender
    Shaikh, Mushtaque S.
    Pissurlenkar, Raghuvir R. S.
    Coutinho, Evans C.
    JOURNAL OF MOLECULAR MODELING, 2010, 16 (07) : 1251 - 1268
  • [3] Molecular modeling study of HIV-1 gp120 attachment inhibitors
    Gadhe, Changdev G.
    Kothandan, Gugan
    Madhavan, Thirumurthy
    Cho, Seung Joo
    MEDICINAL CHEMISTRY RESEARCH, 2012, 21 (08) : 1892 - 1904
  • [4] 3D-QSAR and docking studies on piperidine-substituted diarylpyrimidine analogues as HIV-1 reverse transcriptase inhibitors
    Liu, Xin
    Chen, Xuwang
    Zhang, Lingzi
    Zhan, Peng
    Liu, Xinyong
    MEDICINAL CHEMISTRY RESEARCH, 2015, 24 (08) : 3314 - 3326
  • [5] Docking-based 3D-QSAR study of HIV-1 integrase inhibitors
    Gupta, Pawan
    Roy, Nilanjan
    Garg, Prabha
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2009, 44 (11) : 4276 - 4287
  • [6] 3D-QSAR and molecular docking studies of hydroxamic acids as peptide deformylase inhibitors
    Gao, Jian
    Cheng, Yuanhua
    Cui, Wei
    Chen, Quan
    Zhang, Fushi
    Du, Yuguo
    Ji, Mingjuan
    MEDICINAL CHEMISTRY RESEARCH, 2012, 21 (08) : 1597 - 1610
  • [7] 3D-QSAR and docking studies on pyridopyrazinones as BRAF inhibitors
    Yong Ai
    Shao-Teng Wang
    Chu Tang
    Ping-Hua Sun
    Fa-Jun Song
    Medicinal Chemistry Research, 2011, 20 : 1298 - 1317
  • [8] 3D-QSAR and docking studies on pyridopyrazinones as BRAF inhibitors
    Ai, Yong
    Wang, Shao-Teng
    Tang, Chu
    Sun, Ping-Hua
    Song, Fa-Jun
    MEDICINAL CHEMISTRY RESEARCH, 2011, 20 (08) : 1298 - 1317
  • [9] Molecular docking and 3D-QSAR studies on checkpoint kinase 1 inhibitors
    Hu, Shiyuan
    Yu, Haijing
    Zhao, Lingzhou
    Liang, Aihua
    Liu, Yongjuan
    Zhang, Huabei
    MEDICINAL CHEMISTRY RESEARCH, 2013, 22 (10) : 4992 - 5013
  • [10] CoMFA and CoMSIA 3D-QSAR studies on quionolone caroxylic acid derivatives inhibitors of HIV-1 integrase
    Lu, Peng
    Wei, Xia
    Zhang, Ruisheng
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2010, 45 (08) : 3413 - 3419